Top

Juan Fueyo, M.D., F.A.A.N., F.A.A.A.S.

Department of Neuro-Oncology, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Director of Special Operations, Brain Tumor Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Tenure award, Neuro-Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty Member, The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas

Director of Neuro-Oncology Experimental Research, Neuro-Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty Member, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX

Research Interests

Oncolytic adenoviruses
Cell cycle/apoptosis
Autophagy
p16/Rb/E2F-1 pathway
Molecular therapy
Gliomas
Cancer biology

My laboratory's projects primarily focus on the development of novel gene therapy strategies for the treatment of malignant gliomas. Specifically, I have been examining the mechanisms of cell- cycle control and cell death that are abrogated in brain tumors. Though working mostly on the P16/Rb (retinoblastoma)/E2F-1 pathway, we are also studying the role of p16, Rb, and E2F-1 as tumor suppressor genes in gliomas. In addition, I am in the process of determining whether conventional chemotherapeutics for gliomas can be enhanced when combined with gene therapy. Another related project involves the determination of proficient means of gene delivery using oncolytic viruses. In this regard, we have identified a replication-competent adenovirus (Delta- 24) that cannot bind the Rb protein, has a potent anticancer effect, and low toxicity in quiescent normal cells. The Delta-24 adenoviral construct is currently the target of a provisional patent and is being further realized into a future clinical trial for patients with malignant brain tumors. The focus of my laboratory over the next two years will be on improving the anticancer effect of oncolytic adenoviruses and the translation of those pre-clinical findings to the clinic setting.

if(typeof(dstb)!= "undefined"){ dstb();}

Education & Training

Degree-Granting Education

1997	, Houston, Texas, US, Medicine, ECFMG diploma Medicine
1984	University Autonomous of Barcelona, Barcelona, ES, MD, Doctor in Medicine

Postgraduate Training

1994-1997	Research Fellowship, Experimental Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1985-1992	Clinical Residency, Neurology, University Autonomous of Barcelona, Barcelona

Licenses & Certifications

1984	Medicine and General Surgery

Experience & Service

Editorial Activities

Associate Editor, Frontiers in Oncology, 2023 - Present

Member, Editorial Board, Molecular Therapy — Oncology, 2023 - Present

Member, Editorial Board, Molecular Therapy – Oncolytics, 2014 - 2023

Associate Editor, Autophagy, 2009 - 2018

Associate Editor, Neuro-Oncology, 2007 - 2012

Honors & Awards

2025	Nomination - Potu N. Rao Award for Excellence in Basic Sciences, The University of Texas MD Anderson Cancer Center
2025	Commendation, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
2024	The 2024 Golden Virus Award, International Oncolytic Virotherapy Consortium
2023 - Present	Elected Honorary Member, Association of Spanish Scientists in U.S. (ECUSA)
2022 - Present	Elected Fellow, Alliance for Cancer Gene Therapy (ACGT)
2022	Nomination - McGovern Award for Outstanding Teaching, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
2021 - Present	Elected Fellow, American Association for the Advancement of Science (AAAS)
2021	NCI — Highlight in the National Cancer Act 50th Anniversary Commemoration: Cancer Research Starts Here: Accelerating Our Understanding of Cancer into the Future, National Cancer Institute
2019 - Present	Elected Fellow, American Academy of Neurology (AAN)
2018	Member, Spanish Selection of Science, Spanish National Research Council (CSIC)
2016	American Men and Women in Science
2016	Nomination - Potu N. Rao Award for Excellence in Basic Science, Division of Cancer Medicine Faculty Recognition & Award Program, The University of Texas MD Anderson Cancer Center
2012	Waun Ki Hong Award for Excellence Team Science [Delta-24 program], The University of Texas MD Anderson Cancer Center
2009	Nomination - Waun Ki Hong Award for Excellence Team Science [Delta-24 program], The University of Texas MD Anderson Cancer Center
2003	The Peter A. Steck Memorial Award, The Pediatric Brain Tumor Foundation of the United States of America
2001	American's Registry of Outstanding Professionals, Who's Who
1997	Best Presentation Award, European Neurological Society (ENS)
1995	Travel Award, American Association for Cancer Research (AACR)

Selected Publications

Peer-Reviewed Articles

Lopez-Rivas A, Gillard A, Fueyo J, Gomez-Manzano C. Implications of 9p21.3 deletion for glioma viroimmunotherapy. Neuro-Oncol. e-Pub 2026.
Wu X, Ledbetter D, Tsai J, Singh S, Gumin J, Fan X, Gillard A, Shin DH, Jiang H, Zhao B, Ingram D, Akdmeir K, Conley A, Lazar A, Raza S, North R, Tatsui C, Lang F, Wang W, Rhines L, Gomez-Manzano C, Fueyo J, Alvarez-Breckenridge AC. Oncolytic Adenoviral Infection of Chordoma Achieves Treatment Efficacy through Immunogenic Cell Death and Tumor Microenvironment Alteration. Cancer Research. e-Pub 2025.
Labiano, S, Marco-Sanz, J, Ausejo-Mauleon, I, Laspidea, V, Hernández-Osuna, R, Garcia Moure, M, Nava, Dl, Nuin, S, Gonzalez-Huarriz, M, Phoenix, T, Tamayo, I, Zalacain, M, Lacalle, A, Marrodan, L, Puigdelloses, M, Hervás-Corpión, I, Ochoa, MC, Casares, N, Becher, OJ, Gomez-Manzano, C, Fueyo-Margareto, J, Pérez-Larraya, JG, Patiño-García, A, Alonso, MM. Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. Cell Reports Medicine 6(7), 2025. e-Pub 2025. PMID: 40578365.
de la Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, Zalacain M, Marrodan L, García-Moure M, Ochoa MC, Tallon-Cobos AC, Hernandez-Osuna R, Marco-Sanz J, Dhandapani L, Hervás-Corpión I, Becher OJ, Nazarian J, Mueller S, Phoenix TN, van der Lugt J, Hernaez M, Guruceaga E, Koschmann C, Venneti S, Allen JE, Dun MD, Fueyo J, Gomez-Manzano C, Gállego Pérez-Larraya J, Patiño-García A, Labiano S, Alonso MM. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro-Oncology 26(8):1509-1525, 2024. e-Pub 2024. PMID: 38554031.
Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK, Nguyen TT, Sohoni SS, Lopez-Rivas AR, Parthasarathy A, Ene CI, Gumin J, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther 32(3):722-733, 2024. e-Pub 2024. PMID: 38311852.
Meléndez-Vázquez NM, Nguyen TT, Fan X, López-Rivas AR, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas. Mol Ther Oncol 32(1):200787, 2024. e-Pub 2024. PMID: 38596290.
Kan P, Srinivasan VM, Gumin J, Garcia R, Chen SR, Johnson JN, Collins DE, Chen MM, Ledbetter D, Huse J, Evan Luna ZA, Robledo A, Vasandani V, Rao A, Singh SK, Shpall EJ, Fueyo J, Gomez-Manzano C, Lang FF. Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics. Neuro Oncol 26(1):127-136, 2024. e-Pub 2024. PMID: 37603323.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, He J, Gillard AG, Lang FF, Gomez-Manzano C, Fueyo J. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer Res Commun 3(6):1118-1131, 2023. e-Pub 2023. PMID: 37379361.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, Á L, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 29(6):1370-1378, 2023. e-Pub 2023. PMID: 37188783.
Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer 10(7), 2022. e-Pub 2022. PMID: 35902132.
Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, Patiño-García A, Dobbs J, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, Puigdelloses M, Laspidea V, Astigarraga I, Lopez-Ibor B, Cruz O, Oscoz Lizarbe M, Hervas-Stubbs S, Alkorta-Aranburu G, Tamayo I, Tavira B, Hernandez-Alcoceba R, Jones C, Dharmadhikari G, Ruiz-Moreno C, Stunnenberg H, Hulleman E, van der Lugt J, MÁ I, Diez-Valle R, Esparragosa Vázquez I, Villalba M, de Andrea C, Núñez-Córdoba JM, Ewald B, Robbins J, Fueyo J, Gomez-Manzano C, Lang FF, Tejada S, Alonso MM. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med 386(26):2471-2481, 2022. e-Pub 2022. PMID: 35767439.
Laspidea V, Puigdelloses M, Labiano S, Marrodán L, Garcia-Moure M, Zalacain M, Gonzalez-Huarriz M, Martínez-Vélez N, Ausejo-Mauleon I, de la Nava D, Herrador-Cañete G, Marco-Sanz J, Guruceaga E, de Andrea CE, Villalba M, Becher O, Squatrito M, Matía V, Gállego Pérez-Larraya J, Patiño-García A, Gupta S, Gomez-Manzano C, Fueyo J, Alonso MM. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35393952.
van Putten EHP, Kleijn A, van Beusechem VW, Noske D, Lamers CHJ, de Goede AL, Idema S, Hoefnagel D, Kloezeman JJ, Fueyo J, Lang FF, Teunissen CE, Vernhout RM, Bakker C, Gerritsen W, Curiel DT, Vulto A, Lamfers MLM, Dirven CMF. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. Clin Cancer Res 28(8):1572-1585, 2022. e-Pub 2022. PMID: 35176144.
Shimizu Y, Gumin J, Gao F, Hossain A, Shpall EJ, Kondo A, Parker Kerrigan BC, Yang J, Ledbetter D, Fueyo J, Gomez-Manzano C, Lang FF. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg 136(3):1-11, 2022. e-Pub 2022. PMID: 34450587.
Martinez-Velez N, Laspidea V, Zalacain M, Labiano S, García-Moure M, Puigdelloses M, Marrodan L, Gonzalez-Huarriz M, Herrador G, de la Nava D, Ausejo-Mauleon I, Fueyo J, Gomez-Manzano C, Patiño-García A, Alonso MM. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. Mol Cancer Ther 21(3):471-480, 2022. e-Pub 2022. PMID: 34965961.
Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol 23(11):1911-1921, 2021. e-Pub 2021. PMID: 34059921.
Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34281988.
Garcia-Moure M, Gonzalez-Huarriz M, Labiano S, Guruceaga E, Bandres E, Zalacain M, Marrodan L, de Andrea C, Villalba M, Martinez-Velez N, Laspidea V, Puigdelloses M, Gallego Perez-Larraya J, Iñigo-Marco I, Stripecke R, Chan JA, Raabe EH, Kool M, Gomez-Manzano C, Fueyo J, Patiño-García A, Alonso MM. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clin Cancer Res 27(6):1807-1820, 2021. e-Pub 2021. PMID: 33376098.
Srinivasan VM, Gumin J, Camstra KM, Collins DE, Chen MM, Shpall EJ, Parker Kerrigan BC, Johnson JN, Chen SR, Fueyo J, Gomez-Manzano C, Lang FF, Kan P. Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery 88(1):E102-E113, 2020. e-Pub 2020. PMID: 33231254.
de la Rocha AMA, González-Huarriz M, Guruceaga E, Mihelson N, Tejada-Solís S, Díez-Valle R, Martínez-Vélez N, Fueyo J, Gomez-Manzano C, Alonso MM, Laterra J, López-Bertoni H. miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Arch Clin Biomed Res 4(3):221-238, 2020. e-Pub 2020. PMID: 32905473.
Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
Rivera-Molina Y, Jiang H, Fueyo J, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang FF, Gomez-Manzano C. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv 1(1):vdz009, 2019. e-Pub 2019. PMID: 31608328.
Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun 10(1):2235, 2019. e-Pub 2019. PMID: 31138805.
Martinez-Velez N, Marigil M, García-Moure M, Gonzalez-Huarriz M, Aristu JJ, Ramos-García LI, Tejada S, Díez-Valle R, Patiño-García A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathol Commun 7(1):64, 2019. e-Pub 2019. PMID: 31036068.
Tejada S, Alonso M, Patiño A, Fueyo J, Gomez-Manzano C, Diez-Valle R. Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery, 2018. e-Pub 2018. PMID: 29088386.
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36(14):1419-1427, 2018. e-Pub 2018. PMID: 29432077.
Lang FM, Hossain A, Gumin J, Momin EN, Shimizu Y, Ledbetter D, Shahar T, Yamashita S, Parker Kerrigan B, Fueyo J, Sawaya R, Lang FF. Mesenchymal Stem Cells as Natural Bio-Factories for Exosomes Carrying miR-124a in the Treatment of Gliomas. Neuro Oncol 20(3):380-390, 2018. e-Pub 2018. PMID: 29016843.
Tejada S, Díez-Valle R, Domínguez PD, Patiño-García A, González-Huarriz M, Fueyo J, Gomez-Manzano C, Idoate MA, Peterkin J, Alonso MM. DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. Front Oncol 8:61, 2018. e-Pub 2018. PMID: 29594041.
Hossain MB, Shifat R, Li J, Luo X, Hess KR, Rivera-Molina Y, Puerta Martinez F, Jiang H, Lang FF, Hung MC, Fueyo J, Gomez-Manzano C. TIE2 associates with caveolae and regulates caveolin-1 to promote their nuclear translocation. Mol Cell Biol 37(21), 2017. e-Pub 2017. PMID: 28760776.
Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, Bean AJ, Calin GA, Fueyo J, Walters ET, Kalluri R, Verhaak RG, Lang FF. Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res 77(21):5808-5819, 2017. e-Pub 2017. PMID: 28855213.
Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
Dai B, Roife D, Kang Y, Gumin J, Rios Perez MV, Li X, Pratt M, Brekken RA, Fueyo J, Lang FF, Fleming JB. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16(4):662-670, 2017. e-Pub 2017. PMID: 28138026.
Xipell E, Aragón T, Martínez-Velez N, Vera B, Idoate MA, Martínez-Irujo JJ, Garzón AG, Gonzalez-Huarriz M, Acanda AM, Jones C, Lang FF, Fueyo J, Gomez-Manzano C, Alonso MM. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. Neuro Oncol 18(8):1109-19, 2016. e-Pub 2016. PMID: 26951384.
Xipell E, Gonzalez-Huarriz M, Martinez de Irujo JJ, García-Garzón A, Lang FF, Jiang H, Fueyo J, Gomez-Manzano C, Alonso MM. Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma. Oncotarget 7(21):30626-41, 2016. e-Pub 2016. PMID: 27121320.
Hossain MB, Shifat R, Johnson DG, Bedford MT, Gabrusiewicz KR, Cortes-Santiago N, Luo X, Lu Z, Ezhilarasan R, Sulman EP, Jiang H, Li SS, Lang FF, Tyler J, Hung MC, Fueyo J, Gomez-Manzano C. TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Sci Adv 2(4):e1501290, 2016. e-Pub 2016. PMID: 27757426.
Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, Alonso MM, Lang F, Yung WK, Fueyo J, Gomez-Manzano C. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget 7(13):16146-57, 2016. e-Pub 2016. PMID: 26910374.
Klein SR, Jiang H, Hossain MB, Fan X, Gumin J, Dong A, Alonso MM, Gomez-Manzano C, Fueyo J. Critical role of autophagy in the processing of adenovirus capsid-incorporated cancer-specific antigens. PLoS One 11(4):e0153814, 2016. e-Pub 2016. PMID: 27093696.
Acanda de la Rocha AM, López-Bertoni H, Guruceaga E, González-Huarriz M, Martínez-Vélez N, Xipell E, Fueyo J, Gomez-Manzano C, Alonso MM. Analysis of SOX2-Regulated Transcriptome in Glioma Stem Cells. PLoS One 11(9):e0163155, 2016. e-Pub 2016. PMID: 27669421.
Avci NG, Fan Y, Dragomir A, Akay YM, Gomez-Manzano C, Fueyo J, Akay M. Delta-24-RGD Induces Cytotoxicity of Glioblastoma Spheroids in Three Dimensional PEG Microwells. IEEE Trans Nanobioscience 14(8):946-51, 2015. e-Pub 2015. PMID: 26661633.
Klein SR, Piya S, Lu Z, Xia Y, Alonso MM, White EJ, Wei J, Gomez-Manzano C, Jiang H, Fueyo J. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34(41):5295-301, 2015. e-Pub 2015. PMID: 25619840.
Gabrusiewicz K, Hossain MB, Cortes-Santiago N, Fan X, Kaminska B, Marini FC, Fueyo J, Gomez-Manzano C. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia 17(4):374-84, 2015. e-Pub 2015. PMID: 25925380.
Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo J, Konopleva M, Andreeff M. MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One 10(10):e0139254, 2015. e-Pub 2015. PMID: 26440941.
Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS, Toledo G, Fueyo J, Gomez-Manzano C, Torre W, Lecanda F, Patiño-García A, Alonso MM. The Oncolytic Adenovirus Delta24-RGD in Combination with Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. J Bone Miner Resi 29(10):2287-96, 2014. e-Pub 2014. PMID: 24737304.
Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5(8):2208-20, 2014. e-Pub 2014. PMID: 24809734.
Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 2014. PMID: 24827739.
Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108(10):2005-12, 2013. e-Pub 2013. PMID: 23632480.
Shinojima N, Hossain A, Takezaki T, Fueyo J, Gumin J, Gao F, Nwajei F, Marini FC, Andreeff M, Kuratsu J, Lang FF. TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res 73(7):2333-44, 2013. e-Pub 2013. PMID: 23365134.
Jiang H, White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity. J Virol 85(10):4720-9, 2011. e-Pub 2011. PMID: 21367888.
Piya S, White EJ, Klein SR, Jiang H, McDonnell TJ, Gomez-Manzano C, Fueyo J. The E1B19K Oncoprotein Complexes with Beclin 1 to Regulate Autophagy in Adenovirus-Infected Cells. PLoS One 6(12):e29467, 2011. e-Pub 2011. PMID: 22242123.
Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. Oncotarget 1(8):700-9, 2010. e-Pub 2010. PMID: 21321379.
Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 2010. e-Pub 2010. PMID: 20807803.
Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):289-97, 2010. e-Pub 2010. PMID: 19876078.
Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human Bone Marrow-Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus Delta-24-RGD to Human Gliomas. Cancer Res 69(23):8932-40, 2009. e-Pub 2009. PMID: 19920199.
Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24):2358-63, 2009. e-Pub 2009. PMID: 19421150.
Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256-65, 2009. e-Pub 2009. PMID: 18927600.
Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 2008. e-Pub 2008. PMID: 18708344.
Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, Wang H. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 88(1):11-7, 2008. e-Pub 2008. PMID: 18246408.
Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-93, 2008. e-Pub 2008. PMID: 18253154.
Lee OH, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in glioma. Oncogene 27(9):1310-1314, 2008. e-Pub 2008. PMID: 17704802.
Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the 06-methylguanine-DNA methyltransferase promoter. Cancer Res 67(24):11499-504, 2007. e-Pub 2007. PMID: 18089777.
Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67(22):11054-63, 2007. e-Pub 2007. PMID: 18006852.
Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 15(9):1607-15, 2007. e-Pub 2007. PMID: 17579575.
Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Knodo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4, 2007. e-Pub 2007. PMID: 17848677.
Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 67(17):8255-63, 2007. e-Pub 2007. PMID: 17804740.
Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 2007. e-Pub 2007. PMID: 17557108.
Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4009, 2007. e-Pub 2007. PMID: 17483310.
Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 2006. e-Pub 2006. PMID: 17065226.
Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4:915-26, 2006. e-Pub 2006. PMID: 17189382.
Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5):419-28, 2006. e-Pub 2006. PMID: 16790091.
Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 2006. e-Pub 2006. PMID: 16428500.
Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA, Stephens C, Fueyo J, Jiang H, Conrad C, Fang B. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 13(1):82-90, 2006. e-Pub 2006. PMID: 16037823.
Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 2005. e-Pub 2005. PMID: 16264179.
Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 2005. e-Pub 2005. PMID: 16207474.
Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-94, 2005. e-Pub 2005. PMID: 15650766.
Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. e-Pub 2005. PMID: 15720816.
Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 2004. e-Pub 2004. PMID: 15332115.
Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 2004. e-Pub 2004. PMID: 15014451.
Arap MA, Lahdenranta J, Hajitou A, Marini FC, rd, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R. Model of unidirectional transluminal gene transfer. Mol Ther 9(2):305-10, 2004. e-Pub 2004. PMID: 14759814.
Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 2003. e-Pub 2003. PMID: 12734316.
Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. e-Pub 2003. PMID: 12509854.
Mitlianga PG, Gomez-Manzano C, Kyritsis AP, Fueyo J. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol 21(5):1015-20, 2002. e-Pub 2002. PMID: 12370749.
Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, Alemany R, Fueyo J, Curiel DT, Vassal G, Pinedo HM, Vandertop WP, Gerritsen WR. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62(20):5736-42, 2002. e-Pub 2002. PMID: 12384532.
Adachi Y, Chandrasekar N, Kin Y, Lakka SS, Mohanam S, Yanamandra N, Mohan PM, Fuller GN, Fang B, Fueyo J, Dinh DH, Olivero WC, Tamiya T, Ohmoto T, Kyritsis AP, Rao JS. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21(1):87-95, 2002. e-Pub 2002. PMID: 11791179.
Calbo J, Marotta M, Cascallo M, Roig JM, Gelpi JL, Fueyo J, Mazo A. Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 8(10):740-50, 2001. e-Pub 2001. PMID: 11687897.
Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WK. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 61(18):6693-7, 2001. e-Pub 2001. PMID: 11559537.
Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19(2):359-65, 2001. e-Pub 2001. PMID: 11445852.
Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9):1252-7, 2001. e-Pub 2001. PMID: 11336478.
Mitlianga PG, Kyritsis AP, Gomez-Manzano C, Lemoine MG, Hu M, Liu TJ, Yung WK, Fueyo J. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol 18(2):343-7, 2001. e-Pub 2001. PMID: 11172602.
Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7(1):120-6, 2001. e-Pub 2001. PMID: 11205899.
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1):2-12, 2000. e-Pub 2000. PMID: 10644974.
Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Research 59(4):895-900, 1999. e-Pub 1999. PMID: 10029081.
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4(6):685-90, 1998. e-Pub 1998. PMID: 9623977.
Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 12(6):1391-6, 1998. e-Pub 1998. PMID: 9592205.
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50(5):1307-15, 1998. e-Pub 1998. PMID: 9595979.
Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 1998. e-Pub 1998. PMID: 9472109.
Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 1997. e-Pub 1997. PMID: 9366522.
Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 1997. e-Pub 1997. PMID: 9230885.
Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-9, 1996. e-Pub 1996. PMID: 8895506.
Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 1996. e-Pub 1996. PMID: 8630997.
Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1996. e-Pub 1996. PMID: 8552379.
Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 1995. e-Pub 1995. PMID: 8808318.
Group ES. Silent brain infartaction in nonrheumatic atrial fibrillation. Neurology 46:159-165, 1995. e-Pub 1995.
Fueyo J, Ferrer I, Valldeoriola F, Graus F. The expression of a neuronal nuclear antigen (Ri) recognized by the human anti-Ri autoantibody in the developing rat nervous system. Neurosci Lett 162(1-2):141-4, 1993. e-Pub 1993. PMID: 8121617.
Escudero D, Barnadas A, Codina M, Fueyo J, Graus F. Anti-Ri-associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer. Neurology 43(8):1605-6, 1993. e-Pub 1993. PMID: 8351021.
Graus F, Rowe G, Fueyo J, Darnell RB, Dalmau J. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 150(2):212-4, 1993. e-Pub 1993. PMID: 8469424.
Study Group TEAFT. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333:5-10, 1993. e-Pub 1993.
Group ES. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262, 1993. e-Pub 1993.
Pou Serradell A, Fueyo J, Gomez C, Oliveras C, Espadaler JM, Alameda F, Graus F. [Paraneoplastic encephalomyelitis and Lambert-Eaton syndrome]. Rev Neurol (Paris) 148(10):605-9, 1992. e-Pub 1992. PMID: 1338234.
Meléndez-Vázquez NM, Wieren AV, Sohoni S, Bolaños-Rosero B, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Immune-microbe responses to viroimmunotherapy against gastric cancer: a dynamic multi-kingdom approach. Cancer Discovery.
Ene C, Dr Singh SK, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin NE, Prabhu S, Weinberg JS, Larman B, Gomez-Manzano C, Fueyo J, Lang FF. Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). Clin Cancer Res.
Gomez-Manzano C, Alvarez-Beckeridge C, Shin DH, Guillard A, Alonso M, Lang F, Fueyo J. Diverse Origin and Nature of Tumor Infiltrating Lymphocytes: The Infection Hypothesis. Nature Cancer.

Invited Articles

Shin, DH, Alonso, MM, Gomez-Manzano, C, Fueyo-Margareto, J. Virus Against Cancer: Paradigm-Shifting Biological Concepts. Current Neurology and Neuroscience Reports 25(1), 2025. e-Pub 2025. PMID: 40515944.
Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, Gomez-Manzano C. Targeting Innate Immunity in Glioma Therapy. Int J Mol Sci 25(2), 2024. e-Pub 2024. PMID: 38256021.
Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book 42:1-8, 2022. e-Pub 2022. PMID: 35580289.
Fueyo J, Gomez-Manzano C, Lang FF, Alonso MM. Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses: Stem cell delivery of oncolytic viruses. Lancet Oncol 22(8):1049-1051, 2021. e-Pub 2021. PMID: 34214494.
Ene CI, Fueyo J, Lang FF. Delta-24 adenoviral therapy for glioblastoma: Evolution from the bench to bedside and future considerations. Neurosurg Focus 50(2):E6, 2021. e-Pub 2021. PMID: 33524949.
Klionsky DJ, [...], Fueyo J, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 13:33-39, 2015. e-Pub 2015. PMID: 25863716.
Jiang H, Fueyo J. Healing after death: anti tumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology 3(7), 2014. e-Pub 2014.
Klionsky DJ, [...], Fueyo J, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
Balvers R, Jiang H, Piya S, Gomez-Manzano C, Fueyo J. Adenovirus, Autophagy, and Lysis: Ecstasies and Agonies. Future Virology 6(10):1161-1164, 2011. e-Pub 2011.
Fueyo J, Gomez-Manzano C, Yung WK. Advances in Translational Research in Neuro-Oncology. Arch Neurol 68(3):303-8, 2011. e-Pub 2011. PMID: 21059986.
White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J, Jiang H. Autophagy regulation in cancer development and therapy. Am J Cancer Res 1(3):362-372, 2011. e-Pub 2011. PMID: 21969237.
Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther 12(5):530-7, 2010. e-Pub 2010. PMID: 20886384.
Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med 10(50):24-8, 2010. e-Pub 2010. PMID: 20670595.
Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo J, Gewirtz DA, Kroemer G, Levine B, Mizushima N, Rubinsztein DC, Thumm M, Tooze SA. A comprehensive glossary of autophagy-related molecules and processes. Autophagy 6(4):438-448, 2010. e-Pub 2010. PMID: 20484971.
Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: A paradigm of oncogene addiction. Cancer Lett 263(2):157-63, 2008. e-Pub 2008. PMID: 18334281.
Jiang H, White EJ, Gomez-Manzano C, Fueyo J. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy 4(1):118-20, 2008. e-Pub 2008. PMID: 18032923.
Klionsky DJ, [...], Fueyo J, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2008. e-Pub 2008. PMID: 18188003.
Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23:773-80, 2008. e-Pub 2008. PMID: 18366015.
Gomez-Manzano C, Alonso M, Jiang H, Fueyo J. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2008. e-Pub 2008. PMID: 18756625.
Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6:1585-92, 2006. e-Pub 2006. PMID: 17134363.
Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6(5):697-708, 2006. e-Pub 2006. PMID: 16759161.
Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 2003. e-Pub 2003. PMID: 12700119.
Fueyo J, Gomez-Manzano C, Liu TJ, Yung WK. Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol 51(3):277-87, 2001. e-Pub 2001. PMID: 11407598.
Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 56(4):445-8, 1999. e-Pub 1999. PMID: 10199333.
Fueyo J, Gomez-Manzano C. Molecular control of the cellular cycle and apoptosis: new treatments for gliomas. Neurologia 8:43-47, 1999. e-Pub 1999.

Review Articles

Parthasarathy A, Frost M, Gillard AG, Alonso MM, Gomez-Manzano C, Fueyo J. The multilayered control of acetylation during adenovirus-based immunotherapy of cancer. Mol Ther Oncol 33(2):200976, 2025. e-Pub 2025. PMID: 40236995.
He J, Connors J, Meador A, Xu S, Meador H, Jiang H, Fueyo J, Gomez-Manzano C, Friedman GK, Zaky W, Sadighi Z, Slopis JM, Ahmad AH. Immunotherapy-related neurotoxicity in the central nervous system of children with cancer. Neuro Oncol 27(3):625-643, 2025. e-Pub 2025. PMID: 39535217.
Garcia-Moure M, Laspidea V, Gupta S, Gillard AG, Khatua S, Parthasarathy A, He J, Lang FF, Fueyo J, Alonso MM, Gomez-Manzano C. The emerging field of viroimmunotherapy for pediatric brain tumors. [COVER ISSUE]. Neuro Oncol 26(11):1981-1993, 2024. e-Pub 2024. PMID: 39148489.
He, J, Munir, F, Ragoonanan, D, Zaky, W, Khazal, SJ, Tewari, P, Fueyo-Margareto, J, Gomez-Manzano, C, Jiang, H. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno 3(1):37-56, 2023. e-Pub 2023.
Shin DH, Gillard A, Van Wieren A, Gomez-Manzano C, Fueyo J. Remission of Liquid Tumors and SARS-CoV-2 Infection: a Literature Review. Mol Ther Oncolytics 26:135-140, 2022. e-Pub 2022. PMID: 35702422.
Shin DH, Nguyen T, Ozpolat B, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Current Strategies to Circumvent the Anti-Viral Immunity to Optimize Cancer Virotherapy. J Immunother Cancer 9(4), 2021. e-Pub 2021. PMID: 33795384.
Varela-Guruceaga M, Tejada-Solís S, García-Moure M, Fueyo J, Gomez-Manzano C, Patiño-García A, Alonso MM. Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors. Cancers (Basel) 10(7), 2018. e-Pub 2018. PMID: 29987215.
Jiang H, Martin V, Alonso M, Gomez-Manzano C, Fueyo J. RB-E2F1: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 2010. e-Pub 2010. PMID: 20935482.
Jiang H, Gomez-Manzano C, Lang F, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 9(5):422-7, 2009. e-Pub 2009. PMID: 19860656.
Alonso MM, Fueyo J, Yung WK, Gomez-Manzano C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 5(9):930-5, 2006. e-Pub 2006. PMID: 16628012.
Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 63(3):418-26, 2004. e-Pub 2004. PMID: 15304571.
Alemany R, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus for the treatment of cerebral tumors: past, present and future. Neurologia 16(3):122-7, 2001. e-Pub 2001. PMID: 11333782.
Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12, 1999. e-Pub 1999. PMID: 10502394.
Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3(1):81-5, 1999. e-Pub 1999. PMID: 9864390.
Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 51(5):1250-5, 1998. e-Pub 1998. PMID: 9818841.
Fueyo J, Gomez-Manzano C. Molecular control of the cellular cycle and apoptosis: new treatments for gliomas. Neurologia 13(7):349-55, 1998. e-Pub 1998. PMID: 9810797.

Editorials

Garcia-Moure M, Gillard AG, Alonso MM, Fueyo J, Gomez-Manzano C. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage. Mol Ther Oncol 18(4):781-784, 2024. PMID: 38561242.
Youssef GC, Gomez-Manzano C, Sawaya R, Fueyo J. Antitumor immune response during glioma virotherapy. Neuro Oncol, 2019. PMID: 31348516.
Fueyo J, Alonso MM, Parker Kerrigan BC, Gomez-Manzano C. Linking inflammation and cancer: the unexpected SYK world. Neuro Oncol 20(5):582-583, 2018. PMID: 29635349.
Fueyo J, Hossain MB, Nguyen T, Gomez-Manzano C. Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway. Transl Cancer Res 6(Suppl 2):S317-S320, 2017. PMID: 28944168.
Conrad CA, Fueyo J, Gomez-Manzano C. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16(8):1025-6, 2014. PMID: 25002413.

Abstracts

Jiang H, He J, Duran A, Godina Riera CS, Shin DH, Parthasarathy A, Lopez-Rivas AR, Gillard AG, Lang F, Manzano CG, Fueyo J. Oncolytic Adenoviruses Induce Tertiary Lymphoid Structures in Brain Tumors to Promote Durable Antitumor Immunity. https://ror.org/0481e3r23. e-Pub 2026.
Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, Singh S, Frost M, Fan X, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. A Novel Sensor of Adenovirus and Immune Regulator during oncolytic adenovirotherapy. International Cancer Neuroscience Symposium 2026. e-Pub 2026.
Parthasarathy A, Frost M, Gillard A, Shin DH, Rivas AL, Jiang H, Fan X, Rivera AM, Riera CS, Gomez-Manzano C, Fueyo J. Targeting P300/CBP boosts anti-tumor immune response driven by Delta-24-RGD in pediatric Diffuse Midline Gliomas. International Cancer Neuroscience Symposium 2026. e-Pub 2026.
Lopez-Rivas AR, Shin DH, Parthasarathy A, Gillard AG, Solbes C, Duran A, Gumin J, Alvarez-Breckenridge C, Lang FF, Fueyo J, Gomez-Manzano C. Combining JAK inhibition with oncolytic virotherapy to reprogram immunosuppressive macrophages in glioblastoma. International Cancer Neuroscience Symposium. e-Pub 2026.
Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. Uncovering alternative innate immunity pathways in glioma viroimmunotherapy. Neuro Oncol 27(Supplement_5):217, 2025. e-Pub 2025.
Lopez-Rivas AR, Gillard AG, Parthasarathy A, Shin DH, Frost M, He J, Jiang H, Fan X, Rubio-Ramos S, Duran A, Alonso MM, Lang FF, Alvarez-Breckenridge C, Fueyo J, Gomez-Manzano C. JAK inhibition enhances viroimmunotherapy of gliomas: targeting JAK-guided immunosuppressive pathways. Neuro Oncol 27(Supplement_5):213-214 [Best Poster Award], 2025. e-Pub 2025.
Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. Neuro Oncol 27(Supplement_5):211, 2025. e-Pub 2025.
Wu X, Ledbetter D, Wang W, Singh S, Gumin J, Fan X, Gillard A, Shin DH, Jiang H, Zhao B, Akdemir K, Conley A, Lazar A, Tatsui C, Lang F, Gomez-Manzano C, Fueyo J, Rhines L, Alvarez-Breckenridge C. The oncolytic adenovirus Delta-24-RGD achieves antitumor polarization of the chordoma tumor microenvironment in human and murine models of chordoma. Neuro Oncol 27(Supplement_5):342, 2025. e-Pub 2025.
Jiang H, He J, Duran A, Fan X, Shin DH, Frost M, Parthasarathy A, Lopez-Rivas A, Gillard A, Gumin J, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus armed with immune stimulators: a promising partner for CAR T cell therapy in primary and metastatic malignant brain tumors. Neuro Oncol 27(Supplement_5):364, 2025. e-Pub 2025.
de Larraya JGP, Casares N, Giraldez M, Serrano M, Bejarano B, Dominguez P, Mbongo C, Andrea CD, Gonzalez-Huarriz M, Ausejo-Mauleon I, Honorato C, Martinez-Simon A, Fueyo J, Gomez-Manzano C, Patiño A, Alonso MM. Phase I Trial of Single Intratumoral Injection of DNX-2440 Oncolytic Adenovirus in Recurrent Glioblastoma Patients. Neuro Oncol 27(Supplement_5):137, 2025. e-Pub 2025.
Zaman MF, Singh S, Pirani AM, Hossain A, Gumin J, Ledbetter D, Milutinovic B, Fueyo-Margareto J, Gomez-Manzano C, Lang FF. A New View of Microvascular Proliferation: PDGFRB+ Perivascular Stromal Cells Drive MVP Formation, Immunosuppression and Stemness in Glioblastoma. Neuro Oncol 27(Supplement_5):457 [Oral Platform], 2025. e-Pub 2025.
Du Y, Singh S, Duran A, Ban K, Wu X, Ene C, Gumin J, Jiang H, Peng D, Gomez J, Sebastian M, Nayyar N, Brastianos P, Tawbi H, Davies M, Lang F, Gomez-Manzano C, Fueyo-Margareto J, Alvarez-Breckenridge C. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models. Neuro Oncol 27(Supplement_5):345, 2025. e-Pub 2025.
Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez A, Jiang H, Fan X, Venneti S, Phoenix T, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD. Neuro Oncol 27(Supplement_5):456 [Best Poster Award], 2025. e-Pub 2025.
Lang FF, Shpall E, Weinbereg JS, Ene C, Chen S, Young C, Kamiya C, Fueyo J, Gomez-Manzano C, Peter K. Phase I trial of mesenchymal stem cells carrying Delta-24-RGD given intraarterially in recurrent glioma: Early report. Neuro Oncol 27(Supplement_5):425, 2025. e-Pub 2025.
He J, Duran A, Fan X, Shin DH, Frost MD, Parthasarathy A, Lopez-Rivas AR, Gillard AG, Gumin J, Lang F, Gomez-Manzano C, Fueyo J, Jiang H. Arming oncolytic adenoviruses with immune stimulators: enhancing CAR T cell therapy for malignant primary and metastatic brain tumors. JITC 13(Suppl_2):308, 2025. e-Pub 2025.
Lopez-Rivas AR, Gillard AG, Parthasarathy A, Shin DH, Morales-Rivera A, Solbes C, Duran A, Gumin J, Alvarez-Breckenridge C, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. JAK inhibition enhances virotherapy in gliomas by modulating interferon-driven resistance. American Association of Cancer Research (AACR) Annual Meeting 2026. e-Pub 2025.
Shaim H, Jiang XR, Shanley M, Rafei H, Kang J, Hsu Y, Fan H, Zhang P, Basar R, Daher M, Liang Q, Xiong D, Gumin J, Kotapali V, Jones CM, Gilbert AL, Muniz-Feliciano L, Deyter GM, Banerjee P, Kaplan M, Mendt M, Moore M, Li Y, Fang D, Arachya S, Biederstadt I, Jiang H, Uprety N, Shrestha R, Jia B, Phadatare PR, Bierderstadt A, Daniels P, Munir M, Banjo O, Mohanty V, Dou J, Jiang X, Shpall EJ, Chen K, Jain AK, Lang F, Gomez-Manzano C, Fueyo J, Rezvani K. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells through AP-1 and IRF pathways activation. American Association for Cancer Research (AACR) Annual Meeting 2026. e-Pub 2025.
Parthasarathy A, Frost M, Gillard A, Shin DH, Rivas AL, Jiang H, Fan X, Rivera AM, Riera CS, Gomez-Manzano C, Fueyo J. P300/CBP Blockade Boosts Therapeutic Efficacy of Delta-24-RGD Against Diffuse Midline Glioma. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
Lopez-Rivas AR, Shin DH, Parthasarathy A, Gillard A, Duran A, Gumin J, Alvarez-Breckenridge C, Lang FF, Fueyo J, Gomez-Manzano C. JAK inhibition modulates polarization of macrophages to enhance viroimmunotherapy against gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez A, Jiang H, Fan X, Venneti S, Phoenix T, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
He J, Duran A, Fan X, Shin DH, Frost MD, Parthasarathy A, Lopez-Rivas AR, Gillard AG, Gumin J, Lang F, Gomez-Manzano C, Fueyo J, Jiang H. Arming oncolytic adenoviruses with immune stimulators: enhancing CAR T cell therapy for malignant primary and metastatic brain tumors. Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting 13(Suppl_2):308, 2025. e-Pub 2025.
Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. Novel immunoregulatory roles of NONO and cGAMP in glioma viroimmunotherapy. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
Morales-Rivera A, Fueyo J, Gomez-Manzano C, Gillard A, Lopez-Rivas A, Parthsarathy A, Jiang H, Singh S, Barrio IM, Akdemir K, Reuben A, Ene C, Hudson W, Lang F, Shin DH. Analysis of T Cell Receptors Reveals Biomarkers of Response in Virotherapy-Treated Gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
Jiang H, He J, Duran A, Fan X, Shin DH, Frost M, Parthasarathy A, Lopez-Rivas A, Gillard AG, Gumin J, Lang FF, Candelaria Gomez-Manzano, Fueyo J. Oncolytic adenovirus armed with immune stimulators: a promising partner for CAR T cell therapy in primary and metastatic malignant brain tumors. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
He J, Parthasarathy A, Moure MG, Shin DH, Lopez-Rivas A, Gillard A, Duran A, Fan X, Phoenix T, Lang F, Roldan MA, Fueyo J, Gomez-Manzano C, Jiang H. Locoregional Therapy with Immune Co-stimulator-armed Oncolytic Adenovirus for Diffuse Midline Glioma. Neuro Oncol Pediatr 1(Supplement_1), 2025. e-Pub 2025.
Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. Cancer Neurosciences Program Scientific Retreat. e-Pub 2025.
Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. NONO: A Novel Sensor of Adenovirus and Immune Regulator. Cancer Neurosciences Program Scientific Retreat. e-Pub 2025.
Parthasarathy A, Frost M, He J, Garcia Moure M, Gillard A, Shin DH, Lopez-Rivas A, Alonso M, Gomez-Manzano C, Fueyo J. Combining P300/CBP inhibition with Delta-24-RGDenhances the anti-tumor effect in Diffuse Midline Glioma. 2025 SNO Pediatric Neuro-Oncology Conference 1(Supplement_1), 2025. e-Pub 2025.
He J, Parthasarathy A, Moure MG, Shin DH, Lopez-Rivas A, Gillard A, Duran A, Fan X, Phoenix T, Lang F, Roldan MA, Fueyo J, Gomez-Manzano C, Jiang H. Locoregional Therapy with Immune Co-stimulator-armed Oncolytic Adenovirus for Diffuse Midline Glioma. 2025 SNO Pediatric Neuro-Oncology Conference 1(Supplement_1), 2025. e-Pub 2025.
Parthasarathy A, Frost M, He J, Moure MG, Gillard A, Shin DH, Lopez-Rivas A, Alonso M, Gomez-Manzano C, Fueyo J. Combining P300/CBP inhibition with Delta-24-RGDenhances the anti-tumor effect in Diffuse Midline Glioma. Neuro Oncol Pediatr 1(Supplement_1), 2025. e-Pub 2025.
Parthasarathy A, Frost M, He J, Alonso M, Lang FF, Gomez-Manzano C, Fueyo J. Harnessing Oncolytic Adenoviruses for Targeted Diffuse Midline Glioma Therapy. ChadTough Defeat DIPG Foundation 2025 Research Workshop, 2025. e-Pub 2025.
Gomez Manzano C, Alonso M, Alemany R, Fueyo J. Unmasking the Hidden Challenge: The Core Dilemma of Cancer ViroImmunotherapy. AdenoNet 2025, 2025. e-Pub 2025.
Shin DH, Ozpolat B, Gillard A, Garcia-Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Winning the tug of war between virus and tumor immunodominance in gliomas treated with oncolytic adenoviruses using tolerogenic strategies. Neuro Oncol, 2024. e-Pub 2024.
Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Garcia Moure M, Lang F, Gomez-Manzano C, Fueyo J. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15. Neuro Oncol, 2024. e-Pub 2024.
Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Garcia Moure M, Lang F, Gomez-Manzano C, Fueyo J. Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators. JITC, 2024. e-Pub 2024.
Parthasarathy A, Garcia Moure M, He J, Gillard AG, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton LA, Delaney J, Phoenix TN, Lang F, Alonso M, Young NL, Gomez-Manzano C, Fueyo J. Viroimmunotherapy combined with acetylation suppression: advanced therapeutics for pediatric diffuse midline gliomas. JITC, 2024. e-Pub 2024.
Jiang XR, Rafei H, Basar R, Daher M, Liang Q, Biederstadt I, Zhang P, Xiong D, Kang J, Gumin J, Shanley M, Jones CM, Gilbert AL, Shaim H, Muniz-Feliciano L, Deyter GM, Banerjee P, Moore M, Li Y, Fang D, Arachya S, Jiang H, Uprety N, Shrestha R, Jia B, Daniel P, Munir M, Banjo O, Shpall EJ, Jain AK, Chen K, Lang F, Gomez-Manzano C, Fueyo J, Rezvani K. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells. JITC, 2024. e-Pub 2024.
Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, AI-Atrash G, Lang F, Manzano C, Fueyo J. Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy. JITC, 2024. e-Pub 2024.
Parthasarathy A, Garcia-Moure M, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Phoenix T, Lang F, Young N, Alonso M, Gomez-Manzano C, Fueyo J. Acetylation Suppression Meets Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Glioma. Neuro Oncol, 2024. e-Pub 2024.
Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, AI-Atrash G, Lang F, Manzano C, Fueyo J. Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
Shin DH, Ozpolat B, Gillard A, Garcia-Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Winning the tug of war between virus and tumor immunodominance in gliomas treated with oncolytic adenoviruses using tolerogenic strategies. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
Parthasarathy A, Garcia-Moure M, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Phoenix T, Lang F, Young N, Alonso M, Gomez-Manzano C, Fueyo J. Acetylation Suppression Meets Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Glioma. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang F, Gomez-Manzano C, Fueyo J. Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
Parthasarathy A, Moure MG, He J, Gillard AG, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton LA, Delaney J, Phoenix TN, Lang F, Alonso M, Young NL, Gomez-Manzano C, Fueyo J. Viroimmunotherapy combined with acetylation suppression: advanced therapeutics for pediatric diffuse midline gliomas. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang F, Gomez-Manzano C, Fueyo J. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
Jiang XR, Rafei H, Basar R, Daher M, Liang Q, Biederstadt I, Zhang P, Xiong D, Kang J, Gumin J, Shanley M, Jones CM, Gilbert AL, Shaim H, Muniz-Feliciano L, Deyter GM, Banerjee P, Moore M, Li Y, Fang D, Arachya S, Jiang H, Uprety N, Shrestha R, Jia B, Daniel P, Munir M, Banjo O, Shpall EJ, Jain AK, Chen K, Lang F, Gomez-Manzano C, Fueyo J, Rezvani K. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
Parthasarathy A, Garcia Moure M, He J, Jiang H, Frost M, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Targeting P300-mediated acetylation in Delta-24-RGD-treated diffuse midline gliomas. Mol Ther Oncol, 2024. e-Pub 2024.
Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Nanoparticle-induced virus immune tolerance during oncolytic therapy of gliomas. Eur J Cancer, 2024. e-Pub 2024.
Parthasarathy A, Moure MG, He J, Jiang H, Frost M, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Targeting P300-mediated acetylation in Delta-24-RGD-treated diffuse midline gliomas. 16th Annual International Oncolytic Virotherapy Conference (IOVC 2024), 2024. e-Pub 2024.
Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Nanoparticle-induced virus immune tolerance during oncolytic therapy of gliomas. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024, 2024. e-Pub 2024.
la Nava DD, Ausejo-Mauleon I, Nazarian J, Mueller S, Allen JE, Koschmann C, Venneti S, Dun MD, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. ONC201 Combined with the Oncolytic Adenovirus Delta-24-RGD as a new Therapeutic Regime for Pediatric High-Grade and Diffuse Midline Gliomas. Neuro Oncol 26(Supplement_4):0, 2024. e-Pub 2024.
Parthasarathy A, Garcia-Moure M, He J, Shin DH, Gillard AG, Lopez-Rivas A, Hampton LA, Fan X, Jiang H, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Targeting hyperacetylation in pediatric diffuse midline gliomas using oncolytic adenoviruses. Neuro Oncol 26(Supplement_4):0, 2024. e-Pub 2024.
Fueyo J. ONC201 Combined with the Oncolytic Adenovirus Delta-24-RGD as a new Therapeutic Regime for Pediatric High-Grade and Diffuse Midline Gliomas. International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) 26(Supplement_4):0, 2024. e-Pub 2024.
Parthasarathy A, Garcia-Moure M, He J, Shin DH, Gillard AG, Lopez-Rivas A, Hampton LA, Fan X, Jiang H, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Targeting hyperacetylation in pediatric diffuse midline gliomas using oncolytic adenoviruses. International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) 26(Supplement_4):0, 2024. e-Pub 2024.
Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A chimeric oncolytic adenovirus circumvents neutralizing antibodies developed by patients with recurrent glioblastoma treated with Delta-24-RGD. Neuro Oncol, 2023. e-Pub 2023.
Lang FF, Zadeh G, Nassiri F, Nguyen T, Garcia-Moure M, Alonso MM, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus with modulators of the immune checkpoints. 15th Annual International Oncolytic Virotherapy Conference (IOVC) 2023, 2023. e-Pub 2023.
Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A chimeric oncolytic adenovirus circumvents neutralizing antibodies developed by patients with recurrent glioblastoma treated with Delta-24-RGD. Society for Neuro-Oncology 28th Annual Meeting and Education Day (SNO 2023), 2023. e-Pub 2023.
Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD. 14th International Oncolytic Virotherapy Conference (IOVC) 2023, 2023. e-Pub 2023.
Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single versus multiple injections of oncolytic adenoviruses in a clinical trial suggests strategies to improve cancer virotherapy through immune-evasion strategies. Cancer Immunol Res, 2023. e-Pub 2023.
Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single versus multiple injections of oncolytic adenoviruses in a clinical trial suggests strategies to improve cancer virotherapy through immune-evasion strategies. CICON23 - 7th International Cancer Immunotherapy Conference: Translating Science into Survival, 2023. e-Pub 2023.
Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Immune tolerance for viral antigens facilitates tumoral epitope spreading during oncolytic virotherapy. International Conferences on Brain Tumor Research and Therapy (ICBTRT) 2023, 2023. e-Pub 2023.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Localized intratumoral treatment with adoptive T cell therapy followed by oncolytic adenovirus Delta-24-RGDOX induces sustainable regression of disseminated solid through antigen spread. Neuro Oncol 24(suppl_7):vii231, 2022. e-Pub 2022.
Shin DH, Jiang H, Gillard A, Kim D, Nguyen TT, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Neuro Oncol 24(suppl_7):vii139-vii140, 2022. e-Pub 2022.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. JITC, 2022. e-Pub 2022.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting 2022, 2022. e-Pub 2022.
Jiang H, Shin DH, Yi Y, Fan X, Gillard A, Gupta S, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity. 14th International Oncolytic Virotherapy Conference (IOVC) 2022. e-Pub 2022.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combining oncolytic adenovirus Delta-24-RGDOX with adoptive therapy in localized treatment induces sustainable regression of disseminated solid tumors through antigen spreading. Cancer Res, 2022. e-Pub 2022.
Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combining oncolytic adenovirus Delta-24-RGDOX with adoptive therapy in localized treatment induces sustainable regression of disseminated solid tumors through antigen spreading. American Association for Cancer Research (AACR) Annual Meeting2022, 2022. e-Pub 2022.
Shin DH, Jiang H, Kim D, Nguyen TT, Sohoni S, Fan X, Yi Y, Wieren AC, Al-Atrash G, Bernatchez C, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Redirection of anti-virus immunity towards anti-tumor immunity using nanoparticle-induced immune tolerance for oncolytic adenovirus therapy. American Association for Cancer Research (AACR) Annual Meeting 2022, 2022. e-Pub 2022.
Shin DH, Jiang H, Kim D, Nguyen T, Sohoni S, Fan X, Yi Y, Van Wieren AC, Al-Atrash G, Bernatchez C, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Ozpolat B, Fueyo J. Redirection of anti-virus immunity towards anti-tumor immunity using nanoparticle-induced immune tolerance for oncolytic adenovirus therapy. Cancer Res, 2022. e-Pub 2022.
Jiang H, Shin DH, Sohoni SS, Nguyen TN, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. JITC, 2021. e-Pub 2021.
Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, 2021. e-Pub 2021.
Nguyen T, Shin DH, Jiang H, Wainwright DA, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Gomez-Manzano C, Fueyo J. Inhibition of the IDO-Kyn-AhR cascade optimizes virotherapy in glioblastoma and depends on CD4 T-cell activation. Cancer Res 81(Supplement_13):1785, 2021. e-Pub 2021.
Shin DH, Nguyen TT, Jiang H, Fan X, Yi Y, Sohoni S, Gupta S, Ossimetha A, Gomez-Manzano C, Fueyo J. Evasion of neutralizing antibodies andenhanced anti-tumor effectsof hexon-modified Delta-24-RGD oncolytic adenovirus. Cancer Res 81(Supplement_13):1912, 2021. e-Pub 2021.
Jiang H, Nguyen T, Shin DH, Sohoni S, Gupta S, Yi Y, Fan X, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGDOX collaborates with adoptive T cell therapy to sustain systemic anti-tumor immunity. Cancer Res 81(Supplement_13):1579, 2021. e-Pub 2021.
Shin DH, Nguyen T, Jiang H, Sohoni S, Gupta S, Ossimetha A, Alonso M, Gomez-Manzano C, Fueyo J. Hexon swapping mitigates anti-viralimmune responseduring brain tumor virotherapy. Neuro Oncol 22(suppl 2):ii95, 2020. e-Pub 2020.
Nguyen N, Shin DH, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Combined IDO inhibitor and OX40L-armed-oncolytic-adenovirus therapy improves survival in murine glioblastoma. Cancer Immunol Res 8(Supplement_3):A30, 2019. e-Pub 2019.
Jiang H, Shin DH, Nguyen TT, Lang FF, Gomez-Manzano C, Fueyo J. Systemic immunity against disseminated subcutaneous and intracranial melanomas induced by oncolytic adenovirus Delta-24-RGDOX. JITC 7(suppl_1):283, 2019. e-Pub 2019.
Jiang H, Shin DH, Nguyen TT, Alonso MM, Lang F, Gomez-Manzano C, Fueyo J. Treatment with Delta-24-RGDOX of subcutaneous tumors results in abscopal effect eradicating intracranial melanomas. Neuro Oncol 21(suppl_6):vi84, 2019. e-Pub 2019.
Shin DH, Jiang H, Nguyen T, Youssef G, Fan X, Yi Y, Gomez-Manzano C, Fueyo J. Glioblastoma disguised: combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T-cells. Cancer Res, 2019. e-Pub 2019.
Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen T, Rivera-Molina Y, Lang FF, Gomez-Manzano C, Fueyo J. Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX. Proceedings of the AACR Special Conference - Melanoma: From Biology to Target. e-Pub 2019.
Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang F, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. J Immunother Cancer, 2018. e-Pub 2018.
Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang F, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting 6(Suppl 1):327-328, 2018. e-Pub 2018.
Jiang H, Nguyen T, Shin DH, Fan X, Gumin J, Bernatchez C, Lang F, Gomez-Manzano C, Fueyo J. In situ autovaccination mediated by oncolytic adenovirus Delta-24-RGDOX induces efficacious immunity against metastatic melanoma. Society for Neuro-Oncology, 2018. e-Pub 2018.
Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carrillo CC, Henry VK, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. J Immunother Cancer, 2018. e-Pub 2018.
Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carrillo CC, Henry VK, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 6(Suppl 1):190, 2018. e-Pub 2018.
Jiang H, Nguyen T, Shin DH, Fan X, Gumin J, Bernatchez C, Lang F, Gomez-Manzano C, Fueyo J. In situ autovaccination mediated by oncolytic adenovirus Delta-24-RGDOX induces efficacious immunity against metastatic melanoma. Society for Neuro-Oncology (SNO) 23rd Annual Scientific Meeting and Education Day 20(suppl_6):vi91, 2018. e-Pub 2018.
Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Mino B, Wistuba I, Hess K, Alonso M, Tejada S, Diez-Valle R, Ewald B, Tufaro F, Lang F. Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas. Proceedings of the Am. Assoc. Cancer Res. (AACR), 2018. e-Pub 2018.
Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Mino B, Wistuba I, Hess K, Alonso M, Tejada S, Diez-Valle R, Ewald B, Tufaro F, Lang F. Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington, DC, April 1-5, 2017) 77(13 suppl):LB235, 2018. e-Pub 2018.
Jiang H, Dong A, Carrillo C, Henry V, Fan X, Rivera-Molina Y, Puerta-Martinez F, Nguyen T, Clise-Dwyer K, Lang F, Gomez-Manzano C, Fueyo J. Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. 32nd Annual Meeting of the Society for Immunotherapy of Cancer (National Harbor, MD; Nov. 8-12, 2017), 2017. e-Pub 2017.
Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Wistuba I, Hess K, Alonso M, Tejada S, Diez Valle R, Ewald B, Tufaro F, Lang F. Immunomarkers in the DNX-2401 (Delta-24-RGD) oncolytic virus phase I clinical trial. Neuro-Oncol (22ND Annual Scientific Meeting and Education Day of The Society For Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(suppl_6):vi27, 2017. e-Pub 2017.
Jiang H, Dong A, Rivera-Molina Y, Clise-Dwyer K, Fan X, Puerta Martinez F, Nguyen T, Henry V, Carrillo C, Gomez-Manzano C, Fueyo J. Cancer-killing viruses combined with tumor-targeting immune checkpoint modulation elicits an in situ vaccination effect and expansion of tumor-specific T cells responsible for efficacious systemic anti-cancer activity. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl.):3680 77(13 supl):5890, 2017. e-Pub 2017.
Rivera-Molina Y, Puerta Martinez F, Nguyen T, Jiang H, Fan X, Shifat R, Hossain MB, Henry VK, Carrillo CC, Gomez-Manzano C, Fueyo J. Forced expression of GITRL in cancer cells enhances adenovirus-mediated in situ vaccination. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):4565, 2017. e-Pub 2017.
Lang FF, Tran ND, Puduvalli VK, Elder JB, Fink KL, Conrad CA, Yung WKA, Penas-Prado M, Gomez-Manzano C, Peterkin J, Fueyo F. Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma. Journal of Clinical Oncology (ASCO Annual Meeting, June 2-6 2017, Chicago, IL) 35(15_supp):2002, 2017. e-Pub 2017.
Martinez-Velez N, Marigil Sanchez M, Dominguez P, Aristu JJ, Fueyo J, Gomez-Manzano C, Junier MP, Chneiweiss H, El-harb E, Diez Valle R, Tejada S, Alonso MM. Looking for a cure:Delta-24-RGD and radiotherapy for DIPG treatment. Neuro-Oncol (21st Annual Meeting and Education Day, Scottsdale, Arizona, November 17-20, 2016) 18(suppl.6):vi61, 2016. e-Pub 2016.
Rivera-Molina Y, Hong Jiang H, Puerta Martinez F, Nguyen T, Fan X, Gomez-Manzano C, Fueyo J. Armed-oncolytic virus Delta-24-GREAT expressing GITRL induces potent anti-glioma effect and specific anti-tumor memory. Tumor Immunology and Immunotherapy, American Association for Cancer Research, Boston, MA, October 20-23, 2016, 2016. e-Pub 2016.
Puerta F, Rivera-Molina Y, Jiang H, Dong A, Fan X, Gomez-Manzano C, Fueyo J. Targeting gliomas and metastatic cancer with oncolytic adenoviruses expressing T-cell activators. DNA Tumor Virus Meeting, McGill Cancer Research Center, Montreal, Quebec, Canada, July 18-23, 2016, 2016. e-Pub 2016.
Fueyo J, Jiang H, Gomez-Manzano C. Combination of Oncolytic adenoviruses and immune checkpoint targeting. The 21st International Conference on Brain Tumor Research and Therapy (Okinawa, Japan, April 9-13, 2016), 2016. e-Pub 2016.
Jiang H, Gomez-Manzano C, Lang F, Tufaro F, Yung WKA, Sawaya R, Fueyo J. Combination of Delta-24-RGDOX and anti-PDL1 antibodies induces anti-tumor effect and antiglioma immune memory. Neuro-Oncol (20th Annual Scientific Meeting of the Society for Neuro-Oncology; Nov 19-22, 2014; San Antonio, TX) 17(suppl.5):v114-v115, 2015. e-Pub 2015.
Jiang H, Clise-Dwyer K, Bover L, Lang FF, Gomez-Manzano C, Fueyo J. Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand. J ImmunoTher Cancer (Society for Immunotherapy of Cancer 30th Annual Meeting, National Harbor, MD; November 4-8, 2015) 3(suppl 2):337, 2015. e-Pub 2015.
Jiang H, Gomez-Manzano C, Clise-Dwyre K, Bover L Vence LM, Lang FF, Conrad CA, Toniatti C, Tufaro F, Fueyo J. Delta-24-RGDOX: Expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces anti-tumor effect and antiglioma immune memory. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY (September 16-19, 2015), 2015. e-Pub 2015.
Kelin SR, Jiang H, Gomez-Manzano C, Fueyo J. Role of JNK in the regulation of autophagy in adenovirus-infected cancer cells: clinical implications. 2nd Symposium Autophagy- Across Biology and Medicine; April 24, 2015; Houston, TX, 2015. e-Pub 2015.
Jiang H, Clise-Dwyer K, Bover L, Lang FF, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: an oncolytic adenovirus enhances anti-glioma immunity through expressing the immune checkpoint co-stimulator OX40 ligand. 9th International Conference on Oncolytic Virus Therapeutics; Harvard Medical School; June 13-16, 2015; Boston, MA, 2015. e-Pub 2015.
Jiang H, Fan X, Clise-Dwyer K, Bover L, Gumin J, Ruisaard KE, Mukheef FJ, Lang FF, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: making cancer more “visible” to the immune system. In: Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR), Apr 18-22, 2015; Philadelphia, PA, 2015. e-Pub 2015.
Jiang H, Clise-Dwyer K, Fan X, Gumin J, Mukheef F, Bover L, Toniatti C, Ruisard K, Vence L, Yung WKA, Gomez-Manzano C, Fueyo J. Enhancement of anti-tumor immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. NIH/NCI Cancer Immunology and Immunotherapy: Delivering the Promise; October 9-10, 2014; Bethesda, MD, 2014. e-Pub 2014.
Jiang H, Lang F, Fan X, Gumin J, Bover L, Clise-Dwyer K, Toniatti C, Ruisaard K, Conrad C, Vence L, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting co-stimulatory immune checkpoint proteins with oncolytic adenoviruses. Neuro-Oncol (19th Annual Scientific Meeting of the Society for Neuro-Oncology; Nov 13-16, 2014; Miami, FL) 16(suppl. 5):v112, 2014. e-Pub 2014.
Piya S, Jiang H, Klein SR, Yung WKA, Sawaya R, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses modulate autophagy in cancer cells via sumoylation of LC3. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research (AACR) ; 2014 Apr 5-19; San Diego, CA, 2014. e-Pub 2014.
Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung WKA, Sawaya R, Weinberg J, Prabhu S, Fuller G, Aldape K, Fueyo J. Phase I Clinical Trial of oncolytic Delta-24-RGD (DNX2401) with Biological Endpoints: Implications for Viro-Immunotherapy. Neuro-Oncol (19th Annual Scientific Meeting of the Society for Neuro-Oncology; Nov 13-16, 2014; Miami, FL) 16(Suppl. 5):v162, 2014. e-Pub 2014.
Jiang H, Klein S, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD infection activates T-cell immune response against glioma cells. Neuro-Oncology, 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (November 21-24, 2013, San Francisco, CA) 15(Suppl. 3):iii63, 2013. e-Pub 2013.
Fueyo J, Lang F, Gomez-Manzano C, Yung A, Sawaya, Conrad C. Examination of cancer testis antibodies and Th1/Th2 cytokines as prognosis markers in glioma patients treated with Delta-24-RGD oncolytic adenovirus. 15th International Congress of Immunology (Milan, Italy, August 22-27, 2013):182, 2013. e-Pub 2013.
Fueyo J, Gomez-Manzano C, Conrad C, Yung WKA, Aldape K, Sawaya R, Lang F. Significance of cancer autoantibodies in patients with malignant gliomas treated with Delta-24-RGD. Neurology (65th American Academy of Neurology Meeting, March 16-23, 2013, San Diego, CA) 80, 2013. e-Pub 2013.
Klein S, Jiang H, Piya S, White EJ, Fan X, Lu Z, Yung WKA, Gomez-Manzano C, Fueyo J. C-Jun N-terminal kinases regulate adenovirus-induced autophagy: the implications for cancer immunotherapy using oncolytic adenoviruses. AACR Special Meeting: Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012, Miami, FL, 2012. e-Pub 2012.
Fueyo J, Gomez-Manzano C, Conrad C, Heimberger A, Vence L, Aldape K, Yung WKA, Sawaya R, Fuller G, Lang. Phase I clinical trial in patients with recurrent gliomas: Delta-24-RGD oncolytic adenovirus induces an antiglioma immune-response. Journal of Neurology (Twenty-second meeting of the European Neurological Society, 9-12 June, 2012)(259):S46, 2012. e-Pub 2012.
Fueyo J, Conrad C, Gomez-Manzano C, Heimberger A, Vence L, Aldape K, Yung A, Sawaya R, Fuller G, Lang F. Analyses of anti-cancer testis antigen antibodies in glioma patents treated with Delta-24 oncolytic adenovirus. Cancer Research (AACR 103rd Annual Meeting 2012, March 31-April 4, 2012, Chicago, IL) 72(8, suppl 1), 2012. e-Pub 2012.
Piya S, White E, Klein S, Jiang H, Lang F, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGD modulates autophagy in glioma cells by activation of the Beclin1/PI3KC3 complexes. Neuro-Oncol (16th Annual Meeting of the Society for Neuro-Oncology/AANS/CNS Section on Tumors, Nov 17-20, 2011, Orange County, CA):iii70, 2011. e-Pub 2011.
Jiang H, White E, Rios-Vecil CI, Yung WKA, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces cell lysis through autophagy and autophagy -triggered caspase activity. Neuro-Oncol (16th Annual Meeting of the Society for Neuro-Oncology/AANS/CNS Section on Tumors, Nov 17-20, 2011, Orange County, California:iii116, 2011. e-Pub 2011.
Fueyo J, Gomez-Manzano C, Conrad C, Lang F. Successful translation of Delta-24-RGD: from Bench to the Bedside. The 6th Conference on Oncolytic Adenovirus as Cancer Therapeutics, March 16-19, 2011, Las Vegas, NV, 2011. e-Pub 2011.
Piya S, White EJ, Jiang H, Klein SR, McDonnell TJ, Yung WKA, Gomez-Manzano C, Fueyo J. The oncoprotein E1B19K is part of the Beclin-1 interactome in adenovirus-infected cells. In: Proceedings of the 102th Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL, 2011. e-Pub 2011.
Klein SR, Piya S, White EJ, Jiang H, Yung WKA, Gomez-Manzano C, Fueyo J. JNK1-phosphorylation of Bcl-2 is essential for adenoviral-induced autophagic cell death in glioma cells. In: Proceedings of the 102th Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL, 2011. e-Pub 2011.
Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso MM, White EJ, Xu J, McDonnell T, Shinojima N, Fueyo J. RB/E2F: gatekeepers of autophagy and apoptosis in glioma cells. Neuro-Oncol (15th Annual Meeting of the Society for Neuro-Oncology, Nov 18-21, 2010, Montreal, Canada):iv22, 2010. e-Pub 2010.
Alonso MM, Gomez-Manzano C, Cortes-Santiago N, Roche FP, Fueyo J. Salinomycin overcomes the chemoresistance of Brain Tumor Stem Cells. Neuro-Oncol (15th Annual Meeting of the Society for Neuro-Oncology, Nov 18-21, 2010, Montreal, Canada):iv96, 2010. e-Pub 2010.
J-L L, Mao Z, Xu J, Fueyo J, Yung WKA. Nuclear PTEN-induced autophagy is mediated through induction of ER stress in glioblastoma cells. Neuro-Oncol (15th Annual Meeting of the Society for Neuro-Oncology, Nov 18-21, 2010, Montreal, Canada:iv23, 2010. e-Pub 2010.
Fueyo J, Gomez-Manzano C, Yung WKA, Conrad C, Lang F. Continuous development of delta-24-rgd for the treatment of gliomas. Paper presented at: 8th International Conference on Brain Tumor Research and Therapy, 2010. e-Pub 2010.
Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White EJ, Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F1 in the crossroads of autophagy and apoptosis. In: Proceedings of the 101st Annual Meeting of the Americal Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. Special AACR Conference, Genetics and Biology of Brain Cancers, San Diego, CA,, 2009. e-Pub 2009.
Fueyo J. Successful developmental pathway of Delta-24-RGD. In: Proceedings of the 2009 NCI Translational Science Meeting (TSM 2); 2009 Nov 5-7; Vienna, VA, 2009. e-Pub 2009.
Alonso MM, Liu D, Pabbissety SK, Colman H, Yung WKA, Fueyo J, Gomez-Manzano C. Sox2 plays a pivotal role in the self-renewal property of brain tumor stem cells. Neuro Oncol 11(5):679, 2009. e-Pub 2009.
White E, Jiang H, Gomez-Manzano C, Fueyo J. Adenovirus-induced autophagy requires expression of stress-related kinases but no downregulation of AKT. Neuro Oncol 11(5):573, 2009. e-Pub 2009.
Jiang H, White E, Gumá S, Ji Y, Gomez-Manzano C, Conrad CA, Fueyo J. Enhanced oncolysis of glioma cells by Delta-24-RGD combining with 2-deoxyglucose through autophagic cell death. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009. e-Pub 2009.
Alonso M, Pabbisetty S, Liu D, Xu J, Balasubramaniyan V, Colman H, Fueyo J Gomez-Manzano C. Sox2 is the engine of the self-renewal machinery in brain tumor stem cells. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009. e-Pub 2009.
White EJ, Jiang H, Xu J, Gomez-Manzano C, Fueyo J. Involvement of autophagy in oncolysis: E1A is required but not sufficient. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009. e-Pub 2009.
Jiang H, White E, Alonso M, Xu J, Yung WKA, Gomez-Manzano C, Fueyo J. Detection of autophagy in vivo: Lessons from virotherapy of gliomas. 13th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 10(5):797, 2008. e-Pub 2008.
Liu D, Martin V, Xu J, Fueyo J, Gomez-Manzano C. Role of tie2 signaling in adhesion and the invasive phenotype of gliomas. 13th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 10(5):774, 2008. e-Pub 2008.
Martin V, Alonso MM, Xu J, Liu D, Fueyo J, Gomez-Manzano C. A window for therapy: Tie2 as a new accomplice in the multidrug resistance phenotype of gliomas. 13th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 10(5):796, 2008. e-Pub 2008.
White E, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Atg5 is required for adenovirus-induced autophagy in cancer cells. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
Liu D, Martin V, Xu J, Fueyo J, Gomez-Manzano C. Tie2 signaling mediates adhesion to the endothelial compartment in cancer. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
Martin V, Xu J, Alonso M, Liu D, Fueyo J, Gomez-Manzano C. Tie2 upregulates ABC transporters and promotes drug resistance. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
Alonso M, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
Jiang H, Xu J, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
Alonso M, Gomez-Manzano C, Xu J, Piao Y, Jiang H, Yung WKA, Lang F, Fueyo J. Oncolytic adenoviruses downmodulate MGMT increasing sensibility of brain tumor stem cells to temozolomide: a mechanistic study. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):496, 2007. e-Pub 2007.
Alonso M, Gomez-Manzano C, Jiang H, Xu J, Piao Y, Yokoyama T, Kondo S, Yung WKA, Fueyo J. Delta-24-RGD in combination with RAD001 induces autophagic cell death and 80% long-term survivors. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):491, 2007. e-Pub 2007.
Jiang H, Gomez-Manzano C, Yokoyama T, Alonso M, Kondo S, Xu J, Bekele BN, Colman H, Lang F, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces efficacious antiglioma activity in brain tumor stem cell models. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):496, 2007. e-Pub 2007.
Martin V, Liu D, Xu J, Fueyo J, Gomez-Manzano C. Tie2 mediates adhesion-dependent cell survival in gliomas. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):471, 2007. e-Pub 2007.
Yong R, Fueyo J, Marini F, Hata N, Gumin J, Andreef M, Lang F. Human bone marrow-derived mesenchymal stem cells as delivery vehicles for oncolytic adenovirus Delta-24-RGD in the treatment of malignant glioma. 12th Annual Meeting of the Society for Neuro-Oncology (SNO); In: Neuro Oncol 9(4):591, 2007. e-Pub 2007.
Jiang H, Olson MV, Xu J, Lee OH, Piao Y, Yung WKA, Fueyo J. Exportin 1-mediated nuclear export of adenovirus E1A protein: a novel target for generation of oncolytic viruses. Proc Amer Assoc Cancer Res 47:702-a, 2006. e-Pub 2006.
Andreeff M, Dembinski J, Studeny M, Ling X, Cabreira-Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin RE, Marini FC. Mesenchymal stem cells: Precursors for tumor stroma and targeted delivery vehicles for anticancer agents. Proc Amer Assoc Cancer Res 47:238-b, 2006. e-Pub 2006.
Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Olson MV, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 transcriptionally activates PTEN. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Jiang H, Medrano D, Gomez-Manzano C, LeMoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A Protein Expression as a Novel Strategy to Design Cancer Selective Adenoviruses. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Andreeff M, Dembinski J, Studeny M, Ling X, Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin R, Marini F. Mesenchymal progenitor cells as gene delivery systems for cancer therapy: Tropism and efficacy. Proc Amer Assoc Cancer Res 46:1254, 2005. e-Pub 2005.
Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Icovir-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Neuro-Oncology 7:377, 2005. e-Pub 2005.
Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, J F. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. Neuro-Oncology 7:289, 2005. e-Pub 2005.
Olson M, Jiang H, Medrano D, Gomez-Manzano C, Aldape K, Fueyo J. GFAP-E2F1 transgenic mouse provides the first evidence of an oncogenic role of E2F1 in brain tumor formation. Keystone Conferences: Cellular Senescence and Cell Death, Keystone, CO, 2005. e-Pub 2005.
Jiang H, Alemany R, Gomez-Manzano C, Yung WKA, Sawaya R, Lang F, Fueyo J. Comparison of the Antiglioma Effect of E1A and E1B-55kD-Mutant Oncolytic Adenoviruses. AANS/CNS Section on Tumors Sixth Biennial Satellite Symposium, San Francisco, CA, 2004. e-Pub 2004.
Medrano D, Jiang H, Gomez-Manzano C, Olson M, Lemoine M, Yung WKA, Fueyo J. Replication-competent adenoviruses with impaired p300/CBP binding express low E1A protein levels: implications for oncolytic therapy. 8th Annual Trainee Recognition Day and Research Exposition, The University of Texas M. D. Anderson Cancer Center, Houston, 2004. e-Pub 2004.
Alonso MM, Fueyo J. Direct regulation of telomerase activity by E2F1 in cancer and normal cells. EMBO Workshop / 58th Harden Conference-Telomeres and Genome Stability, Cambridge, UK, 2004. e-Pub 2004.
Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J. E2F1 upregulates telomerase: cell-cycle related telomerase activity in sarcoma cells. 95th Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Gomez-Manzano C, Xu J, Fueyo J, Aldape KD, Bekele BN, Lemoine MN, Fuller GN, Yung WKA. Significant correlation of Angiopoietin-2 and Nestin expression in glioblastomas. Proc Amer Assoc Cancer Res 45:830, 2004. e-Pub 2004.
Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA, Fueyo J. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. 95th Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Medrano D, Jiang H, Johnson D, Aldape K, Olson M, Gomez-Manzano C, Fueyo J. Transgenic overexpression of E2F1 in the brain in E2F4 null background results in severe hydrocephalus similar to E2F5 null mice. Special AACR Conference on Cell Cycle and Cancer: Pathways and Therapies, Fort Lauderdale, FL, 2004. e-Pub 2004.
Andreeff M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, Yang HY, McQueen T, Fueyo J, Champlin RE, Pasqualini R, Lang F, Marini FC. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy. Proc Amer Assoc Cancer Res 45:1304-a, 2004. e-Pub 2004.
Alonso MM, Aldape K, Gomez-Manzano C, Kondo Y, Fueyo J. Is E2F1 driven force behind telomerase activity in glioblastomas? . 10th Annual Poster Session in Neuroscience, University of Texas, Houston, 2003. e-Pub 2003.
Gomez-Manzano C, Jiang H, Stolarek R, Lang FF, Yung WKA, Fuller GN, Fueyo J. U-87 MG Animal Model: predictability of growth kinetics and its use in oncolytic therapy for gliomas. Special AACR Meeting, Orlando, FL, 2003. e-Pub 2003.
Conrad CC, Ji Y, Gumin J, Lang FF, Sawaya R, Yung WKA, Fueyo J. Direct comparison of the antiglioma effects of Delta-24-hyCD and Ad-hyCD. Neuro-Oncology 5:298-299, 2003. e-Pub 2003.
Jiang H, Medrano D, Gomez-Manzano C, Courmier F, Yung WKA, Fueyo J. Replication competent adenoviruses with impaired p300/CBP binding express low E1A proteins levels: implication for oncolytic therapy. Neuro-Oncology 2:301-302, 2003. e-Pub 2003.
Fueyo J, Gomez-Manzano C, Yung WKA, Sawaya R, Lang FF. Dose dependence antiglioma effect of Delta-24-RGD in the intracranial U-87 MG animal model. Neuro-Oncology 5:300-301, 2003. e-Pub 2003.
Alonso M, Aldape K, Gomez-Manzano C, Kondo Y, Fueyo J. Is E2F1 driven force behind telomerase activity in glioblastomas?. Neuro-Oncology 5:288, 2003. e-Pub 2003.
Fueyo J, Gomez-Manzano C, Jiang H, Lemoine M, Stolarek R, Courmier F, Jasti S, Conrad C, Yung WKA. Oncolytic adenoviruses, CPT-11, and topoisomerase I: Mechanisms underlying chemosensitization. Neuro-Oncology 4:322, 2002. e-Pub 2002.
Fueyo J, Gomez-Manzano C, Alemany R, Lemoine M, Stolarek R, Jasti S, Courmier F, Jiang H, Lamfers M, Dirven C, Curiel D, Yung WKA. Oncolytic adenovirus for glioma therapy. Neuro-Oncology 4:S35, 2002. e-Pub 2002.
Fueyo J, Gomez-Manzano C, Lemoine MG, He J, Khan A, Conrad C, Yung WK, Lang FF. Characterization of the Anti-Glioma Effect of a Second-Generation Conditionally Replicating Adenovirus Unable to Bind Rb and p53. Neuro-Oncol 3:290, 2001. e-Pub 2001.
Fueyo J, Lemoine MG, Gomez-Manzano C, Rao S, Lang FF, Conrad C, Groves M, Yung WK. Chemotherapy enhancement of the antiglioma effect of the Delta-24 adenovirus. Neuro-Oncol 3:289-290, 2001. e-Pub 2001.
Groves MD, Lemoine M, Gomez-Manzano C, Mitlianga P, Yung WKA, Fueyo J. E2F-1 increases the chemosensitivity of human glioma cells to temozolomide and BCNU. Neurology 56:A480, Suppl. 3, 2001. e-Pub 2001.
Fueyo J, Gomez-Manzano C, Fuller FN, et al. Treatment of gliomas xenografts with D24 oncolytic adenovirus: a pathological study. Neurology 8:A407, Suppl. 3, 2001. e-Pub 2001.
Conrad CA, Gomez-Manzano C, Fuller GN, Lemoine M, Khan A, Lang FF, T-J L, Yung WKA, Fueyo J. Genome modifications and chemotherapy enhancement of D24 antiglioma effect. Neurology 56:A407-8, Suppl. 3, 2001. e-Pub 2001.
Mitlianga P, Gomez-Manzano C, Lemoine M, Hu M, Liu TJ, Levin VA, Yung WKA, Kyritsis AP, Fueyo J. E2F-2 enhances p53 anti-glioma effect. Neuro-Oncol 2:278, 2000. e-Pub 2000.
Fueyo J, Gomez-Manzano C, Alemany R, et al. Insertion of an RGD motif enhances the oncolytic effect of the D-24 adenovirus. Proc Am Assoc Cancer Res 41:352, 2000. e-Pub 2000.
Fueyo J, Khan A, Gomez-Manzano C, et al. Treatment of intracranial gliomas with D24-RGD. Neuro-Oncol 2:263, 2000. e-Pub 2000.
Fueyo J, Gomez-Manzano C, Lemoine M, Mitlianga P, Yung WKA, Kyritsis AP. Induction of S phase by E2F-1, E2F-2, and E2F-4 enhances the effect of temozolomide on glioma viability. J Neurol 247:III/61, Suppl, 2000. e-Pub 2000.
Fueyo J, Gomez-Manzano C, Alemany R, Yung WKA, Kyritsis AP. Redirecting adenoviruses to glioma: RGD-D24 infects glioma cells by adenovirus receptor-independent system. Neurology 54:A35-A35, Suppl. 3, 2000. e-Pub 2000.
Fueyo J, Khan A, Gomez-Manzano C, et al. Treatment of intracranial gliomas with D24 adenovirus. J Neurol 247:III/61, Suppl. 3, 2000. e-Pub 2000.
Fueyo J, Gomez-Manzano C, Alemany R, et al. Targeting the E2F pathway with tumor-selective adenovirus. Neurology 52 Suppl. 2:A474-A474, 1999. e-Pub 1999.
Fueyo J, Gomez-Manzano C, Mitlianga P, Lee PSY, Yung WKA, Kyritsis AP. Delta-24 oncolytic adenovirus has antiglioma effect in vivo. Neuro-Oncology 1:311, 1999. e-Pub 1999.
Fueyo J, Lee PSY, Alemany R, et al. A new tool for glioma treatment: a mutant adenovirus that replicates predominantly in dividing cells with alter expression of Rb. Proc Am Assoc Cancer Res 39:513, 1998. e-Pub 1998.
Fueyo J, Gomez-Manzano C, Yung WKA, Martin-Duque P, Levin VA, Kyritsis AP. E2F-dependent glioma apoptosis in the absence of transcriptional activation of E2F-target genes. Proc Am Assoc Cancer Res 39:138, 1998. e-Pub 1998.
Fueyo J, Gomez-Manzano C, Lee PSY, et al. A novel tumor specific replication restricted adenoviral vector for glioma therapy. J Neurol 245:461, 1998. e-Pub 1998.
Fueyo J, Gomez-Manzano C, Lee PSY, et al. A novel tumor specific replication restricted adenoviral vector for glioma therapy. J Neurol 245:461, 1988. e-Pub 1988.
Fueyo J, Gomez-Manzano C, Alemany R, et al. A single adenoviral vector able to transfer p53 and p16 for treatment of p53-resistant gliomas. J Neurol 245:460, 1988. e-Pub 1988.
Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez-Rivas A, Fan X, Jiang H, Angelis, Solbes C, Venneti S, Phoenix T, Alonso M, Gomez-Manzano C, Fueyo J. Pharmacological inhibition of P300 boosts immune infiltration induced by Delta-24-RGD in H3K27-altered Diffuse Midline Glioma. 22nd International Symposium on Pediatric Neuro-Oncology (ISPNO 2026).

Book Chapters

Martinez-Velez N, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. Oncolytic Virotherapy for Gliomas: A Preclinical and Clinical Summary. In: Gene Therapy in Neurological Disorders. 1st. Academic Press (Elsevier), 357-384, 2018.
Xipell E, Rivera-Molina Y, Gomez-Manzano C, Jiang H, Alonso M, Alemany R, Fueyo J. Conditionally Replicative Adenoviruses- Clinical Trials. In: Adenoviral Vectors for Gene Therapy. 2nd. Elsevier, 335-348, 2016.
Balvers RK, Gomez-Manzano C, Jiang H, Piya S, Klein SR, Lamfers MLM, Dirven CMF, Fueyo J. Advances in Oncolytic Virotherapy for Brain Tumors. In: Gene Therapy of Cancer. 3rd. Elsevier, 137-152, 2014.
Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene Therapy. In: Handb Clin Neurol. 3rd. Elsevier, 331-8, 2012.
Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. In: Methods Mol Biol. Springer Science & Humana Press, 111-25, 2012.
Alonso M, Fueyo J, Gomez-Manzano C. Malignant Gliomas: Role of E2F1 Transcription Factor. In: Tumors of the Central Nervous System. Volume 1. Springer, 89-97, 2011.
Jiang H, Fueyo J. Gene Therapy of Brain Tumors. In: Gene-based Therapies for Cancer. 1st. Springer Science + Business Media and Humana Press, 17-32, 2010.
Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. In: Methods Enzymology: Autophagy in Disease and Clinical Applications. Part C. Academic Press, 273-86, 2009.
Alonso MM, Fueyo J, Johnson DG, Gomez-Manzano C. The oncogenic role of E2F1 in brain tumors. In: Control of Cellular Physiology by E2F Transcription Factors. Research Signpost, 257-270, 2008.
Alonso MM, Gomez-Manzano C, Alemany R, Jiang H, McCormick F, Fueyo J. Conditionally replicative adenoviruses as antitumoral agents: Past, present and future. In: Cancer and Gene Therapy. Transworld Research Network, 41-54, 2007.
Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. BC Decker Inc, 293-326, 2006.
Fueyo J, Gomez-Manzano C, McDonnell TJ. Cell Cycle and Apoptosis in Human Brain Tumors. In: Human Brain Tumors. Humana Press Inc, 2005.
Fueyo J, Gomez-Manzano C, McDonnell TJ. Regulation of Cell-Cycle and Apoptosis in Human Brain Tumors. In: Brain Tumors. In series: Contemporary Cancer Research. Part II. Humana Press Inc, 249-264, 2005.
Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene-Based Therapy for Gliomas: Targeting the Cancer Genome. In: Genomic and Molecular Neuro-Oncology. Jones and Bartlett Publishers, Inc, 283-302, 2003.
Gomez-Manzano C, Fueyo J, Yung WKA. Gene therapy approaches for gliomas. In: Brain Cancer. In series: American Cancer Society Atlas of Clinical Oncology. BC Decker, 219-237, 2001.
Gomez-Manzano C, O-H L, Xu J, Fueyo J, Yung WKA. Neovascularization of malignant gliomas. In: Molecular Neuro-Oncology: Gliomas Methods and Protocols, In series: Methods in Molecular Medicine. Humana Press Inc, 2000.
Gomez-Manzano C, Fueyo J, Kyritsis AP, Yung WKA. Tumor suppressor gene therapy for brain tumors. In: Gene Therapy for Neurological Disorders & Brain Tumors. Humana Press Inc, 205-230, 1998.

Letters to the Editor

Fueyo J, Gomez-Manzano C, Pascual J, Pou A. Paraneoplastic syndromes. Neurology 43: 236, 1993.
Gomez Manzano C, Fueyo J, Pedro-Botet Montoya J, Fernandez-Sola J. [Bezafibrate-induced necrotizing myopathy]. Med Clin (Barc) 96: 439, 1991.
Fueyo J, Oliveras C, Pou A, Espadaler JM. Proposal for a clinical definition of blepharokolysis. Mov Disord 6: 185-6, 1991.
Gomez Manzano C, Fueyo J, Miralles R, Gutierrez J. [Wernicke's encephalopathy in a female patient with the acquired immunodeficiency syndrome]. Med Clin (Barc) 95: 754-5, 1990.
Gomez Manzano C, Fueyo J, Garces JM, Gutierrez J. [Internuclear ophthalmoplegia related to opiate overdose]. Med Clin (Barc) 94: 637, 1990.
Ros E, Fueyo J, Llach J, Moreno A, Latorre X. Isospora belli infection in patients with AIDS in Catalunya, Spain. N Engl J Med 317: 246-7, 1987.

Less

CV information above last modified August 07, 2026

Juan Fueyo, M.D., F.A.A.N., F.A.A.A.S.

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Editorial Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Viroimmunotherapy Laboratory

Neuro-Oncology department

Cancer Medicine division

Help #EndCancer

Juan Fueyo, M.D., F.A.A.N., F.A.A.A.S.

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Editorial Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Viroimmunotherapy Laboratory

Neuro-Oncology department

Cancer Medicine division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson